Cerebral amyloid angiopathy (CAA) is pathologically defined as the deposition of amyloid protein, most commonly the amyloid β peptide (Aβ), primarily within the media and adventitia of small and medium-sized arteries of the leptomeninges, cerebral and cerebellar cortex.
Since the first description of neurovascular amyloid deposition in 1909 by Gustav Oppenheim, sound scientific evidence has supported the concept that the associated disruption of the overall structure of those small vessels predisposes to both ischaemic small vessel disease and cerebral haemorrhage. [2] [3] [4] Sporadic CAA is a major cause of lobar intracerebral haemorrhage (ICH) and cognitive decline in the elderly, including the normotensive population. 5, 6 Hereditary forms of CAA are generally rare, usually more severe and earlier in onset. Rare non-Aβ familial CAAs can also present clinically with lobar ICH. 7 Regarding sporadic CAA, two major challenges persist:
• a definitive diagnosis requires a neuropathological exam; and 8 • no treatment or preventive strategy for CAA or CAA-ICH has been firmly established.
Nevertheless, in the last decades of research, there has been remarkable progress in our understanding of this condition. CAA pathology has been associated with markers of small vessel disease, including lobar cerebral microbleeds (CMB) and white matter hyperintensities on magnetic resonance imaging (MRI). [9] [10] [11] The availability of MRI sequences that are particularly sensitive to susceptibility effects like the T2* gradient-recalled echo (GRE) and susceptibility weighted imaging (SWI) now allow reliable assessment of an individual's haemorrhagic burden over time and reasonable accuracy by clinical and neuroimaging diagnostic criteria. [10] [11] [12] [13] As our understanding of CAA pathophysiology evolves, specific targets have been identified as candidates for the prevention and treatment of this condition. 14 As new research tools such as the Pittsburgh Compound B (PiB) or other amyloid-imaging agents for positron emission tomography (PET) scan become incorporated into clinical practice, it may also be possible to detect vascular amyloid deposition in the brain noninvasively in living patients, perhaps before an ICH or significant cognitive decline. 15 This article focuses on our current understanding of the pathophysiology of sporadic CAA, the new imaging modalities and laboratory biomarkers that may aid in its detection and the currently available evidence that could guide the management of patients with this condition.
Pathophysiology and Genetics of Sporadic Cerebral Amyloid Angiopathy
Sporadic CAA is the most frequent form of the disease, mostly occurring in the elderly and defined by the accumulation of Aβ in the vessel walls of capillaries, arterioles and small and medium-sized arteries of the cerebral cortex, leptomeninges, and cerebellum. Sporadic CAA is not associated with other systemic, primary or secondary, amyloidosis.
The Aβ peptide is the normal proteolytic product of the integral membrane protein Aβ precursor protein (APP), encoded by the APP gene on chromosome 21. [16] [17] [18] [19] Aβ occurs as 40 or 42 amino acid species (Aβ40, Aβ42) and its generation from APP requires two enzymatic events: a proteolytic cleavage at the amino terminus of the Aβ sequence by β-secretase; and a cleavage at the carboxyl terminus by γ-secretase. [16] [17] [18] [19] Via mechanisms that remain still unknown, soluble Aβ forms undergo a change in conformation, resulting in a predominantly β-sheet structure, highly prone to oligomerisation, fibrillisation and deposition. These deposits can trigger a secondary cascade of events that include release of inflammatory components, activation of the complement system, oxidative stress, alteration of the blood-brain barrier (BBB) permeability and cell toxicity. [20] [21] [22] Aβ in CAA is structurally similar to the peptide that constitutes senile plaques in Alzheimer's disease (AD). In contrast to Alzheimer plaques, however, a substantial proportion of vascular deposits in CAA is of the shorter Aβ40 species. 20 Increases in the Aβ40/42 ratio appears to favour vascular over parenchymal amyloid deposition. 22 The cascade of events that promotes cerebrovascular Aβ accumulation is still not fully understood but an imbalance between Aβ production and clearance is likely to play a key role. 22 Deposited Aβ appears to derive from neurons although circulating Aß may play a seeding function for brain deposition, since intraperitoneal inoculation with Aβ-rich extracts can induce CAA in transgenic mice over expressing APP. [22] [23] [24] [25] Recent data from animal models indicate that ischaemic strokes may trigger accelerated amyloid build-up, most likely through interference with clearance pathways. 26 The mechanism of blood vessel rupture in CAA is still under debate.
Amyloid deposition has been associated with reduced vascular compliance, cracking and weakening of the vessel wall that predispose to vascular rupture and subsequent extravasation of blood to brain parenchyma. 27 CAA pathology is common in the elderly, with a prevalence from 10-50 % of the general elderly population, in autopsy series. 34, 35 Some CAA pathology is also present in nearly all brains with AD and advanced CAA is present in approximately 25 % of AD brains. 35, 36 However, fewer than 50 % of CAA cases meet the pathological criteria for AD.
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Genetics of Sporadic Cerebral Amyloid Angiopathy
The apolipoprotein E (APOE) ε4 and ε2 alleles are genetic risk factors associated with risk of developing sporadic CAA-related ICH. 37,38 APOE ε2 exerts a protective effect on AD risk but increases risk of ICH in CAA patients. 39, 40 The ε2 allele is predominantly associated with vasculopathic changes that predispose to rupture of the diseased vessels, whereas ε4 is related to the severity of amyloid deposition within the vessel wall. 41, 42 Interestingly, recent studies have found that possession of APOE ε2 predisposes individuals with lobar ICH to haematoma expansion. 43, 44 This effect was more pronounced in patients with amyloid angiopathy-related ICH, consistent with the ε2 allele's role in vascular amyloid deposition and vessel fragility.
More recently, the CR1 gene has also been linked to risk of CAA-related ICH, recurrent CAA and CAA pathology burden.
ICHs in the elderly. The clinical manifestations of CAA-related ICH are similar to other types of ICH. The signs and symptoms depend on the size and location of the bleed and may include headache, focal neurological deficits, seizures and altered level of consciousness. 45 In a retrospective analysis of consecutive patients with non-traumatic SAH, CAA was found to be a common cause of SAH in the elderly and clinically presents with single or recurrent focal transient neurological events of short duration. 47 CAA has also been recognised as a probable cause of ischaemic small vessel disease. 48, 49 Indeed, amyloid deposits can narrow the vessel lumen, impair cerebral blood flow regulation, cause alterations in endothelial structure and function and influence vessel dilation in response to physiologic stimuli. [50] [51] [52] Progression of CAA ischaemic burden may lead to cognitive decline and ultimately to vascular dementia. 53 A subset of patients with CAA-related inflammation may present with subacute cognitive decline, seizures and diffuse radiographic white matter abnormalities attributed to vasogenic oedema. 54, 55 The APOE ε4/ε4 genotype has been associated with CAA-related inflammation Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy
and evidence of CAA-related vasculitis or perivascular inflammation on pathologic examination. 56 
Histological Diagnosis
Definitive diagnosis of CAA requires histopathological exam. Congo red staining for amyloid under light microscopy (see Figure 1A ) has been the classical method for amyloid staining, although its sensitivity is relatively low. 57 Immunohistochemistry with fluorescent antibodies specific for Aβ (see Figure 1B) is increasingly used to identify amyloid accumulation in the brain.
Neuroimaging
MRI sequences that are particularly sensitive to susceptibility effects like GRE and SWI can identify not only major bleeding in the brain but also CMBs, which may not be visible on other imaging modalities (see Figure 2) . 12, 58 CMBs have hypointense signal on GRE sequences due to haemosiderin, a blood breakdown product that causes magnetic susceptibility-induced dephasing, leading to T2* signal loss. The appearance of microbleeds on GRE sequences is larger than the actual tissue lesions because of the so-called blooming effect of the magnetic resonance signal at the border of these lesions. 12, 57, 58 Novel techniques such as SWI have considerably increased microbleed detection rates.
59-61
The ability of MRI to detect CMBs has greatly aided the non-invasive diagnosis of CAA during life. As haemosiderin remains in macrophages for many years after haemorrhage, MRI sequences that are particularly sensitive to susceptibility effects allow for reliable assessment of an individual's haemorrhagic burden over time. Haemorrhage burden identified by MRI predicts clinically important events in survivors of lobar ICH. 62 Detection of microhaemorrhages is therefore useful for assessing risk of functional deterioration in CAA patients as well as for risk of future ICH. 62 It is noteworthy that CAA-related CMB, like CAA pathology and CAA-related-ICH, tend to cluster in posterior brain regions.
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Non-traumatic subarachnoid haemorrhage (SAH) and superficial siderosis are also common in patients with CAA. 63, 64 Superficial siderosis may be found at sites distant from ICH and in close vicinity to lobar CMBs, suggesting that SAH can also occur as a primary manifestation of CAA.
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Boston Criteria
Using a combination of clinical, neuroimaging and pathological data, the Boston criteria establish three levels of certainty for the diagnosis of CAA: definite, probable and possible. These criteria were based on the tendency for CAA-related haemorrhages to occur in elderly patients, to be multiple and primarily located in lobar brain regions. 13 As fully described in Table 1 , the diagnosis of probable or possible CAA can be reached by clinical and neuroimaging findings alone without requiring pathological confirmation. 13, 68 The modified Boston criteria include superficial siderosis as one of the required lobar haemorrhagic lesion, which has been reported to improve the sensitivity of the diagnosis without lowering its specificity (see Figure 3) . 64 
Positron Emission Tomography Imaging
PET imaging with Pittsburgh compound B (PiB) has been used in research to measure the burden and location of brain fibrillar Aβ deposits in animal models and in humans with AD or CAA.
15,69-72 Global
PiB retention is elevated in non-demented CAA subjects relative to healthy control subjects (see Figure 4) , although lower in CAA than in AD subjects. 3 Importantly, the occipital-to-global PiB ratio was found to be significantly greater in CAA than in patients with AD. 15 Increased occipital PiB retention was further demonstrated in a young subject with early Iowa-type hereditary CAA, a rare hereditary form of CAA in 
A: Computed tomography (CT) scan showing large right frontal intracerebral haemorrhage (ICH); B: magnetic resonance imaging (MRI) gradient recalled echo (GRE) sequence showing the large frontal lobar haematoma and several additional lobar microbleeds.

Gradient recalled echo (GRE) showing cortical siderosis on the right parietal lobe and a lobar microbleed on the left frontal lobe.
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Figure 1: Histopathological Sections from a Patient with Definite Cerebral Amyloid Angiopathy Confirmed by Congo Red Stain (A) and Immunostaining (B), Demonstrating Vascular Amyloid Deposition
which the fibrillar amyloid deposits appear to be entirely vascular. concentrations of Aβ42 protein and increased tau protein, which allows reasonably accurate differentiation between AD patients and controls (sensitivity and specificity generally >80 %). [75] [76] [77] [78] [79] [80] [81] [82] [83] More recently, CSF concentrations of both Aβ42 and Aβ40 were shown to be reduced in non-demented CAA subjects compared to both healthy controls and AD subjects. 83 These results suggest that the large component of Aβ40 deposited in vessels in advanced CAA may deplete this peptide from CSF, similarly to AD-associated reductions of Aβ42. Total and phosphorylated tau protein levels were not significantly different in CAA from controls. The combination of Aβ42 and total tau strongly discriminated CAA from controls (area under the receiver operator curve, 0.98), although discrimination between CAA and AD was less distinct (area under the receiver operator curve, 0.82). 83 Taken together, these data suggest that Aβ40, Aβ42, and tau protein levels in the CSF may be useful biomarkers of advanced CAA pathology.
Management of Patients with Cerebral Amyloid Angiopathy
There is no evidence-based treatment or preventive strategy specific 
Anti-thrombotic Medications
Anticoagulation with warfarin increases mortality after ICH and may not be safe following CAA-related ICH. 84 While selected patients with deep hemispheric ICH at particularly high risk for thromboembolic stroke and low risk of ICH recurrence might benefit from long-term anticoagulation, patients with CAA-related ICH and atrial fibrillation should not be offered long-term anticoagulation. 84 A small case-control study found an association between the presence of CMBs and warfarin-related ICH, 85 but the relative risks and benefits of anticoagulation in patients with
CMBs are less clear. At least two observational studies found that antiplatelet therapy increased the risk of recurrent CAA-related ICH, particularly for individuals with larger numbers of microbleeds. 86, 87 Larger, more definitive studies are required to settle these important questions, which could have considerable clinical implications.
Management of Co-morbidities
In the Perindopril protection against recurrent stroke study (PROGRESS), blood pressure lowering treatment using perindopril plus optional indapamide was found to provide protection against both ischaemic and haemorrhagic stroke. 88 Further post hoc analysis indicated that randomisation to the blood pressure-lowering regimen reduced risk for CAA-related ICH in particular, suggesting that blood pressure reduction may have benefits in this population. 89 
Management of Cerebral Amyloid Angiopathy-related Intracerebral Haemorrhage
There is no evidence that the acute medical management of patients with CAA-associated ICH should differ from other causes of ICH. 90 Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy • multiple haemorrhages restricted to lobar, cortical or corticosubcortical regions (cerebellar haemorrhage allowed)
• age ≥55 years A subgroup analysis of the Surgical trial in intracerebral haemorrhage (STICH) II suggested better functional outcomes after surgery in patients with superficial as well as lobar ICH in the absence of IVH. 91 The ongoing STICH II will specifically test the benefits of early surgical evacuation for lobar haematomas within 1 cm of the cortical surface without intraventricular extension. 92 The results of this trial will have particular bearing on the surgical management of patients with CAA-related ICH, as lobar ICH is the hallmark of this condition. 93 
Management of Inflammatory Cerebral Amyloid Angiopathy
The inflammatory presentation of CAA represents a potentially treatable form of the disease. Corticosteroid treatment has been shown in some case reports and small series to ameliorate symptoms associated with CAA-related inflammation, possibly by reducing vasogenic oedema. 94 Other immunosuppressant treatments have been reported to influence the course of inflammatory CAA, but available evidence is limited. 95 DiFrancesco and colleagues reported a patient with CAA-related inflammation who was found to have elevated auto-antibodies to Aβ40
and Aβ42 in CSF with subsequent reductions following corticosteroid treatment, offering a potential biological mechanism for this syndrome. 96 If this finding can be confirmed, titres of CSF anti-Aβ antibodies might serve as a biological marker for the diagnosis, monitoring and evaluation of treatment in CAA-related inflammation.
Genetic Testing and Counselling
The over-representation of the APOE ε2 allele in patients with warfarin-associated lobar ICH highlights a future potential for identifying high-risk patients for anticoagulation. 97 The APOE ε2 allele has also been associated with larger baseline ICH volumes, haematoma expansion, presence of spot sign on initial CT angiography and poor outcome in lobar ICH. 43, 44 Nevertheless, there is currently not enough scientific evidence to support routine APOE genotyping of CAA patients for clinical purposes out of an investigational protocol. 98, 99 Mutations of APP as well as other genes unrelated to Aß such as cystatin C, BRI and transthyretin have been associated to familial CAA. [100] [101] [102] [103] [104] [105] Interestingly, different carriers of the same mutation may have dramatically different clinical presentationss. 105 Genetic testing and counselling may be appropriate to patients with a strong family history of lobar ICH or vascular dementia. When faced with those uncommon cases, it is reasonable to offer referral to an academic research centre for further genetic evaluation, differential diagnosis and follow-up.
Conclusions
Since 
